CHARAKTERYSTYKA BIAŁEK WIRUSA EPSTEINA-BARR – ICH UDZIAŁ W ZAKAŻENIU LATENTNYM I POWIĄZANIE Z PROCESAMI NOWOTWORZENIA
1. Wprowadzenie. 2. Perspektywa historyczna. 3. Budowa genomu. 4. Zakażenie pierwotne – mechanizmy wnikania wirionów i replikacji EBV. 5. Molekularne podstawy zakażenia latentnego EBV. 6. Białka fazy latentnej. 7. Reaktywacja zakażenia latentnego. 8. Wirusowe homologi białek komórkowych. 9. Właściwości onkogenne EBV. 10. Nowotwory powiązane z EBV. 11. Podsumowanie
Abstract: Although the Epstein-Barr virus (EBV) infects more than 90% of the human population, the infection can have a broad range of health consequences. The primary infection usually occurs during childhood, without any symptoms or with a mild illness. During adolescent infection mononucleosis occurs in around 50% of individuals. This most extensively studied gammaherpesvirus is also associated with various human malignancies such as Hodgkin`s and non-Hodgkin`s lymphomas, Burkitt`s lymphoma, nasopharyngeal carcinoma, AIDS-related lymphoproliferative disorders and X-linked lymphoproliferative disorder (Duncan`s disease). All these tumors are associated with the EBV latency cycle. Latently infected lymphocytes express the six nuclear antigens (EBNA-1, -2, -3A, -3B, -3C and -LP), three latent membrane proteins (LMP-1, -2A and -2B) and small, non-polyadenylated RNAs (EBER-1 and EBER-2). EBV can transform and immortalise resting B-cells in cultures, which suggests that it may have oncogenic specificity. EBV has broad spectrum of proteins, which mimic cellular proteins regulating cell cycle (BCRF-1, BDLF-2, BARF-1 and BHRF-1). These proteins interact with or exhibit homology to a wide variety of antiapoptotic molecules, cytokines and signal transducers, hence promoting EBV infection, immortalization and transformation.
1. Introduction. 2. Historical perspectives. 3. Genome structure. 4. Primary infection-mechanisms of virion invasion and EBV replication. 5. Molecular aspects of latent EBV infection. 6. Latent proteins. 7. Reactivation from latency. 8. Viral homologues of cellular proteins. 9. Oncogenic properties of EBV. 10. Cancers connected with EBV. 11. Summary